An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours (RAISIC-1).

Single oral intake of PTT-4256 followed by treatment-free period of 3 days to assess safety, PK and PD. After 72-hr post dose PK sample, first 21day cycle of once daily PTT-4256 will begin to assess DLTs. Cohorts A1-A4 will receive 10mg, 20mg, 40mg \& 80mg. Following review by SRC, Cohort A5 participants will receive 160mg PTT-4256 daily